DCM
APLS

DAFNA Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

DAFNA Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-57,746
Closed -$3.81M – 74
2023
Q1 		$3.81M Sell
57,746
-25,700
-31% -$1.48M 1.14% 28
2022
Q4 		$4.31M Buy
83,446
+17,500
+27% +$928K 1.22% 24
2022
Q3 		$4.5M Sell
65,946
-30,989
-32% -$1.83M 1.21% 29
2022
Q2 		$4.38M Buy
96,935
+3,000
+3% +$137K 1.19% 26
2022
Q1 		$4.77M Buy
+93,935
New +$4.15M 1.24% 24
2021
Q3 		– Sell
-12,703
Closed -$803K – 82
2021
Q2 		$803K Sell
12,703
-32,223
-72% -$1.66M 0.17% 75
2021
Q1 		$1.93M Buy
44,926
+1,010
+2% +$47.8K 0.46% 53
2020
Q4 		$2.51M Buy
43,916
+13,862
+46% +$586K 0.75% 35
2020
Q3 		$907K Sell
30,054
-3,500
-10% -$105K 0.29% 57
2020
Q2 		$1.1M Sell
33,554
-20,500
-38% -$658K 0.32% 54
2020
Q1 		$1.45M Buy
54,054
+13,397
+33% +$476K 0.6% 39
2019
Q4 		$1.25M Sell
40,657
-129,143
-76% -$3.57M 0.43% 53
2019
Q3 		$4.09M Buy
+169,800
New +$4.67M 1.54% 18

Other funds holding APLS

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's APLS Position: Q2 2023 in Review

DAFNA Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2023, closing a stake of 57,746 shares — an estimated $3.81M sold.

DAFNA Capital Management first reported a position in APLS in Q3 2019 and held it in 13 quarters. The position peaked at $4.77M in Q1 2022. 316 funds tracked by Wall St. Rank hold APLS as of Q2 2023.

  • DAFNA Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • DAFNA Capital Management sold 57,746 Apellis Pharmaceuticals shares in Q2 2023, an estimated $3.81M.
  • DAFNA Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 13 quarters.
  • DAFNA Capital Management's Apellis Pharmaceuticals position peaked at $4.77M in Q1 2022.
  • 316 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2023.

Based on DAFNA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.